HC Wainwright reiterated their buy rating on shares of Pharming Group (NASDAQ:PHAR – Free Report) in a research report report published on Thursday, Benzinga reports. The brokerage currently has a $37.00 price target on the stock.
Pharming Group Stock Up 4.8 %
Pharming Group stock opened at $8.70 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The business’s 50-day simple moving average is $8.05 and its two-hundred day simple moving average is $8.53. The company has a market cap of $585.89 million, a PE ratio of -54.38 and a beta of 0.15. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20.
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The company had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same quarter in the previous year, the company earned $0.02 EPS. Equities analysts anticipate that Pharming Group will post -0.15 EPS for the current year.
Hedge Funds Weigh In On Pharming Group
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
- Five stocks we like better than Pharming Group
- Trading Halts Explained
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Are Dividend Champions? How to Invest in the Champions
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Investing in the High PE Growth Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.